First-in-Human Clinical Trial
CLINIVAL INVESTIGATION
The ASKEL Cartilage Implant is not yet available for commercial use but has entered the clinical trial phase. It is intended for the surgical treatment of chondral and osteochondral lesions in the knee joints of adult patients.
The first-in-human clinical trial is evaluating the preliminary safety and performance of the ASKEL Cartilage Implant in the treatment of cartilage defects. It is an open-label, non-randomized, prospective clinical investigation involving 20 patients who received the ASKEL Cartilage Implant as part of cartilage repair surgery. The intended clinical benefit of the ASKEL Cartilage Implant is to allow immediate full weight-bearing on the operated leg after surgery, enabling early rehabilitation and a faster return to normal activities.
Patient recruitment has been completed, and the trial is continuing with long-term follow-up of the treated patients. Final results are expected by the end of 2029.
Teemu Paatela, MD, PhD, (Terveystalo, Finland)
is the Coordinating Investigator for the multicenter trial.
VISIT: Clinicaltrials.gov
Pivotal Clinical Trial
Patient recruitment is expected to begin in 2027. More information will follow.
ASKEL Cartilage Implant is an investigational device and is not yet approved for commercial use in any country.
I N T E R E S T E D ?
Have questions about Askel Healthcare or the ASKEL Cartilage Implant? Get in touch with our team – we’d be happy to hear from you.